Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Meusch, Undine ^a   Klingner, Maria ^a   Baerwald, Christoph ^a   Rossol, Manuela ^a   Wagner, Ulf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSMEMBRANE TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; MONOCYTE; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890503696     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4416     Document Type: Article

References (25)

1. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima SI, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005, 128:376-392. 10.1053/j.gastro.2004.11.060, 15685549.
2. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima SI, Hatta H, Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008, 58:1248-1257. 10.1002/art.23447, 18438840.
3. Rossol M, Schubert K, Meusch U, Schulz A, Biedermann B, Grosche J, Pierer M, Scholz R, Baerwald C, Thiel A, Hagen S, Wagner U. Tumor necrosis factor receptor type I expression of CD4+ T cells in rheumatoid arthritis enables them to follow tumor necrosis factor gradients into the rheumatoid synovium. Arthritis Rheum 2013, 65:1468-1476. 10.1002/art.37927, 23494522.
4. Makrygiannakis D, Catrina AI. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis. J Rheumatol 2012, 39:679-685. 10.3899/jrheum.110974, 22422498.
5. Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009, 60:2612-2621. 10.1002/art.24778, 19714631.
6. Srivastava S, Macaubas C, Deshpande C, Alexander HC, Chang SY, Sun Y, Park JL, Lee T, Begovich A, Mellins ED. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin Immunol 2010, 136:257-268. 10.1016/j.clim.2010.04.003, 2902595, 20462799.
7. Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK, Pope RM. Rheumatoid arthritis synovial macrophages express the FAS-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein and are refractory to FAS-mediated apoptosis. Arthritis Rheum 2001, 44:21-30.
8. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, Detmar M, Kyburz D. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 2011, 70:1866-1873. 10.1136/ard.2010.148957, 21742641.
9. Rossol M, Meusch U, Pierer M, Kaltenhäuser S, Häntzschel H, Hauschildt S, Wagner U. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007, 179:4239-4248.
10. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472-475. 10.1126/science.8332913, 8332913.
11. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732. 10.1182/blood-2010-07-273417, 3083294, 21304099.
12. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995, 92:1714-1718. 10.1073/pnas.92.5.1714, 42590, 7878046.
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien T, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588. 10.1136/ard.2010.138461, 20699241.
14. Van Gestel AM, Prevoo ML, Hof MA VT, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of rheumatology and the world health organization/international league against rheumatism criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105, 8546736.
15. Waldmann TA. Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc Natl Acad Sci 1998, 95:14308-14313. 10.1073/pnas.95.24.14308, 24369, 9826696.
16. Steven MM, Lennie SE, Sturrock RD, Gemmell CG. Enhanced bacterial phagocytosis by peripheral blood monocytes in rheumatoid arthritis. Ann Rheum Dis 1984, 43:435-439. 10.1136/ard.43.3.435, 1001366, 6378106.
17. Lioté F, Boval-Boizard B, Weill D, Kuntz D, Wautier JL. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. Clin Exp Immunol 1996, 106:13-19. 2200557, 8870692.
18. Wright HL, Chikura B, Bucknall RC, Moots RJ, Edwards SW. Changes in expression of membrane TNF, NF-(kappa) B activation and neutrophil apoptosis during active and resolved inflammation. Ann Rheum Dis 2011, 70:537-543. 10.1136/ard.2010.138065, 21109521.
19. van der Poll T, Coyle SM, Kumar A, Barbosa K, Agosti JM, Lowry SF. Down-regulation of surface receptors for TNF and IL-1 on circulating monocytes and granulocytes during human endotoxemia: effect of neutralization of endotoxin-induced TNF activity by infusion of a recombinant dimeric TNF receptor. J Immunol 1997, 158:1490-1497.
20. Arend WP, Malyak M, Smith MF, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994, 153:4766-4774.
21. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995, 96:38-41. 10.1172/JCI118045, 185170, 7615809.
22. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004, 138:323-329. 1809217, 15498044.
23. Catrina AI, Trollmo C, Af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72. 10.1002/art.20764, 15641091.
24. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162. 10.1002/art.11098, 12905468.
25. Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh Weerman MA, Smeets TJ, Vervoordeldonk MJ, Baeten B, Tak PP. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum 2008, 58:3330-3339. 10.1002/art.23989, 18975323.